These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 25597119)

  • 21. [Principles of modern therapy for hemophilia A and B in childhood].
    Ströder J; Ambs E
    Dtsch Med Wochenschr; 1968 Mar; 93(12):539-41. PubMed ID: 5639667
    [No Abstract]   [Full Text] [Related]  

  • 22. Stretching time.
    Savage N
    Sci Am; 2015 Jan; 312(1):S8-10. PubMed ID: 25597117
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibitors in haemophilia: a primer.
    DiMichele DM
    Haemophilia; 2000 Jul; 6 Suppl 1():38-40. PubMed ID: 10982266
    [No Abstract]   [Full Text] [Related]  

  • 24. Overview of hemophilia.
    Sergis-Deavenport E; Miller R; Gomperts E
    Issues Compr Pediatr Nurs; 1983; 6(5-6):317-28. PubMed ID: 6421781
    [No Abstract]   [Full Text] [Related]  

  • 25. Blood and neoplastic diseases. Haemophilia and related disorders.
    Rizza CR
    Br Med J; 1974 Oct; 4(5935):36-8. PubMed ID: 4547674
    [No Abstract]   [Full Text] [Related]  

  • 26. Current concepts in diagnosis and management of hemophilia.
    Aledort LM
    Hosp Pract (Off Ed); 1982 Oct; 17(10):77-84, 89-92. PubMed ID: 6811410
    [No Abstract]   [Full Text] [Related]  

  • 27. The molecular basis of haemophilia A and B.
    Giannelli F; Green PM
    Baillieres Clin Haematol; 1996 Jun; 9(2):211-28. PubMed ID: 8800501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Production of antihemophilic factor in France.
    Allain JP
    Scand J Haematol Suppl; 1984; 40():499-503. PubMed ID: 6433471
    [No Abstract]   [Full Text] [Related]  

  • 29. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 32. Animal models of inhibitors.
    Reipert B; Arruda V; Lillicrap D
    Haemophilia; 2010 Jul; 16 Suppl 5():47-53. PubMed ID: 20590856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thirty years of haemophilia treatment in Oxford.
    Biggs R
    Br J Haematol; 1967 Jul; 13(4):452-63. PubMed ID: 6029949
    [No Abstract]   [Full Text] [Related]  

  • 36. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
    Wu RH; Wu XY; Zhang NN; Zhao L; Zhang JS; Zhen YZ; Peng Y
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
    [No Abstract]   [Full Text] [Related]  

  • 38. A therapeutic alternative for haemophiliacs with inhibitors.
    Schulman S
    Acta Paediatr; 1992; 81(6-7):564-5. PubMed ID: 1392376
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn-Malmö protocol.
    Schlabe S; van Bremen K; Goldmann G; Oldenburg J; Eis-Hübinger AM; Zeitler H; Spengler U
    Haemophilia; 2019 Mar; 25(2):e117-e120. PubMed ID: 30694010
    [No Abstract]   [Full Text] [Related]  

  • 40. Prophylactic factor replacement in hemophilia.
    Carcao MD; Aledort L
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.